First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

1. Arranz, R.
2. García-Noblejas, A.
3. Grande, C.
4. Cannata-Ortiz, J.
5. Sánchez, J.J.
6. García-Marco, J.-A.
7. Aláez, C.
8. Pérez-Calvo, J.
9. Martínez-Sánchez, P.
10. Sánchez-González, B.
11. Canales, M.-A.
12. Conde, E.
13. Martín, A.
14. Arranz, E.
15. Terol, M.-J.
16. Salar, A.
17. Caballero, D.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2013.088377 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

•